GSK files Rotarix for prevention of rotavirus in Japan

GlaxoSmithKline announced Nov. 30 that it has filed its vaccine for the prevention of rotavirus gastroenteritis (approved as Rotarix in several countries outside of Japan).

The candidate vaccine, which is given orally, is the first to be filed for approval for the prevention of rotavirus gastroenteritis in infants in Japan.

Rotavirus infection is the leading cause of severe acute gastroenteritis in infants.

GlaxoSmithKline is researching both medicines and vaccines for the World Health Organization’s three priority diseases – HIV/AIDS, tuberculosis and malaria. The company is based in the United Kingdom with operations based in the United States.